Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
193K
-
Shares change
-
+111K
-
Total reported value, excl. options
-
$722K
-
Value change
-
+$416K
-
Number of buys
-
3
-
Price
-
$3.74
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2023
3 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q4 2023.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 193K shares
of 114M outstanding shares and own 0.17% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13.2M shares), BlackRock Inc. (11.2M shares), VANGUARD GROUP INC (9.29M shares), Bellevue Group AG (4.85M shares), D. E. Shaw & Co., Inc. (3.58M shares), Point72 Asset Management, L.P. (3.49M shares), JOHNSON & JOHNSON (3.38M shares), CITADEL ADVISORS LLC (2.67M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.62M shares), and ACADIAN ASSET MANAGEMENT LLC (2.28M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.